An 80‑year‑old woman presents with a bleeding tophus on the right elbow, pancytopenia (white blood cell count 2.8 ×10⁹/L, hemoglobin 6.1 g/dL, platelet count 68 ×10⁹/L), acute kidney injury (creatinine 168 µmol/L), hyponatremia (serum sodium 129 mmol/L), and markedly elevated uric acid (652 µmol/L). What is the appropriate diagnosis and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnosis and Management

This patient requires immediate hospitalization with urgent management of life-threatening pancytopenia, severe anemia requiring transfusion, acute kidney injury, and hyponatremia, while addressing the bleeding tophaceous gout with local wound care and corticosteroids—NOT colchicine or NSAIDs given her severe renal impairment.

Primary Diagnoses

1. Tophaceous Gout with Bleeding Complication

  • Bleeding tophus on right elbow confirms severe, chronic tophaceous gout
  • Markedly elevated uric acid (652.2 µmol/L; normal <360 µmol/L) indicates poor disease control
  • This patient has a strong indication for urate-lowering therapy given the presence of tophi 1

2. Acute Kidney Injury (AKI)

  • Creatinine 167.78 µmol/L (approximately 1.9 mg/dL) represents significant renal impairment in an elderly woman
  • Low BUN (5.03 mmol/L) relative to creatinine suggests possible malnutrition or liver dysfunction
  • The combination of AKI with hyponatremia is common and typically prerenal in origin 2

3. Severe Pancytopenia

  • WBC 2.8 × 10⁹/L (leukopenia)
  • Hemoglobin 6.1 g/dL with hematocrit 17.8% (severe anemia)
  • Platelets 68 × 10⁹/L (thrombocytopenia)
  • This triad requires urgent investigation for bone marrow failure, medication toxicity, or systemic disease

4. Hyponatremia

  • Sodium 128.9 mmol/L (mild-moderate hyponatremia)
  • In the context of AKI, likely represents prerenal azotemia with volume depletion 2

Immediate Management Priorities

Critical Actions (First 24 Hours)

1. Transfusion Support

  • Packed red blood cells: Hemoglobin 6.1 g/dL requires urgent transfusion to prevent cardiovascular decompensation in an elderly patient
  • Platelet transfusion: With active bleeding and platelet count 68 × 10⁹/L, transfuse to maintain platelets >50 × 10⁹/L 3
  • Monitor for transfusion reactions and volume overload given renal impairment

2. Bleeding Control

  • Local wound care for bleeding tophus: sterile dressing, gentle compression
  • Avoid surgical debridement until coagulopathy corrected
  • Surgery only indicated for nerve compression, mechanical impingement, or infection 4

3. Acute Gout Flare Management

  • Oral corticosteroids are the ONLY safe option: Prednisolone 30-35 mg/day for 3-5 days 5
  • AVOID colchicine: Absolutely contraindicated with severe renal impairment (creatinine 167.78 µmol/L) due to risk of neurotoxicity and muscular toxicity 5
  • AVOID NSAIDs: Contraindicated with severe renal impairment and thrombocytopenia 5
  • Consider intra-articular corticosteroid injection if single joint involved and no infection present 5, 4

4. Fluid Resuscitation

  • Isotonic saline for prerenal AKI and hyponatremia correction 2
  • Target gradual sodium correction: no more than 8-10 mmol/L in first 24 hours to avoid osmotic demyelination
  • Monitor urine output, daily weights, and volume status closely

5. Nephrotoxin Avoidance

  • Review and discontinue all nephrotoxic medications
  • Hold any diuretics (common cause of hyponatremia and prerenal AKI) 4
  • Avoid contrast media exposure 6

Diagnostic Workup

Urgent Laboratory Investigations

  • Peripheral blood smear: Rule out microangiopathic hemolytic anemia, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS)
  • Reticulocyte count: Assess bone marrow response to anemia
  • Direct antiglobulin test (Coombs): Rule out autoimmune hemolytic anemia
  • Lactate dehydrogenase (LDH), haptoglobin, indirect bilirubin: Assess for hemolysis
  • Vitamin B12, folate, TSH: Evaluate for nutritional/endocrine causes of pancytopenia
  • Liver function tests: Assess hepatic synthetic function
  • Coagulation studies (PT/INR, aPTT, fibrinogen): Rule out disseminated intravascular coagulation (DIC)

Bone Marrow Examination

  • Strongly indicated given unexplained pancytopenia
  • Aspirate and biopsy to evaluate for:
    • Myelodysplastic syndrome (common in elderly)
    • Aplastic anemia
    • Bone marrow infiltration (lymphoma, metastatic disease)
    • Megaloblastic anemia
    • Drug-induced marrow suppression

Medication Review

  • Obtain complete medication history including over-the-counter drugs and supplements
  • Many medications cause pancytopenia (antibiotics, anticonvulsants, chemotherapy agents, immunosuppressants)

Infection Workup

  • Blood cultures (bacterial, fungal)
  • Urinalysis and urine culture
  • Chest X-ray
  • Consider viral serologies (HIV, hepatitis B/C, EBV, CMV, parvovirus B19)

Subsequent Gout Management (After Stabilization)

Urate-Lowering Therapy (ULT)

This patient has a STRONG indication for ULT given presence of tophi 1

Timing: Initiate ULT after acute flare resolves (typically 2-4 weeks), not during acute attack 5

First-line agent:

  • Allopurinol starting at 50 mg daily given severe renal impairment (creatinine 167.78 µmol/L) 5, 4, 1
  • Titrate slowly by 50-100 mg every 2-4 weeks with close monitoring for adverse events 4
  • Target serum urate <300 µmol/L (5 mg/dL) for tophaceous gout to facilitate crystal dissolution 5, 4

Alternative agents if allopurinol not tolerated:

  • Febuxostat: Can be used without dose adjustment in renal impairment 4
  • Benzbromarone: Alternative uricosuric (avoid if eGFR <30 mL/min) 5

Flare Prophylaxis During ULT Initiation:

  • Low-dose corticosteroids (e.g., prednisone 5-10 mg daily) for 6 months 5
  • AVOID colchicine prophylaxis given severe renal impairment and risk of toxicity 5

Common Pitfalls to Avoid

  1. Do NOT use colchicine or NSAIDs in this patient—both are contraindicated with severe renal impairment and will worsen outcomes 5

  2. Do NOT start ULT during acute flare—this will precipitate further flares and worsen symptoms 5

  3. Do NOT correct hyponatremia too rapidly—risk of osmotic demyelination syndrome; target <10 mmol/L increase in first 24 hours

  4. Do NOT transfuse platelets prophylactically unless count <10 × 10⁹/L or active bleeding present 3

  5. Do NOT overlook medication-induced pancytopenia—many common drugs cause bone marrow suppression

  6. Do NOT delay bone marrow biopsy—unexplained pancytopenia in elderly patient requires definitive diagnosis

Monitoring Parameters

  • Daily: CBC, electrolytes, creatinine, urine output, vital signs, bleeding assessment
  • Every 2-3 days: Reticulocyte count (assess marrow recovery)
  • Weekly: Liver function tests, uric acid (once stable)
  • Ongoing: Volume status, transfusion requirements, infection surveillance

Disposition and Follow-up

  • Admit to monitored bed (intermediate care or ICU if hemodynamically unstable)
  • Hematology consultation for pancytopenia management
  • Nephrology consultation for AKI management and future ULT dosing
  • Rheumatology consultation for long-term gout management after stabilization
  • Post-discharge: Close follow-up within 1 week to reassess blood counts, renal function, and plan ULT initiation

References

3
Research

Thrombocytopenia: Evaluation and Management.

American family physician, 2022

6
Research

Acute kidney injury: a guide to diagnosis and management.

American family physician, 2012

Related Questions

In a 60‑year‑old patient with recent vomiting, diarrhea, abdominal pain, on lisinopril, who now has acute kidney injury with elevated urine sodium, low urine osmolality, and low urine specific gravity, which diagnosis is most likely: pre‑renal azotemia, acute tubular necrosis, or chronic kidney disease?
How should I manage a patient with acute on chronic kidney injury who now has hyperkalemia, hyperphosphatemia, an anion gap of 13, and an eGFR of about 30 mL/min/1.73 m²?
What is the recommended management algorithm for acute kidney injury?
What is the appropriate initial management for an adult patient with 3‑day fever, 4‑day watery diarrhea (4‑5 stools per day), vomiting, oliguria, dry mucous membranes, serum sodium 106 mmol/L, potassium 2.8 mmol/L, bicarbonate 15 mmol/L, creatinine 4.2 mg/dL, urea 77 mg/dL, and stable vital signs?
What is the appropriate management of severe hyponatremia in a patient with prerenal acute kidney injury?
What is the appropriate management for an acute bacterial furuncle in the left nostril presenting with headache and fever?
How should I manage a patient with severe hypercalcemia (corrected calcium 12.5 mg/dL) and an abdominal mass?
When should insulin 70/30 be initiated and how should it be started in a patient with capillary blood glucose of 360 mg/dL and hemoglobin A1c of 12.5%, and can empagliflozin and linagliptin be added?
When is CT angiography indicated and what are the preparation and protocol considerations?
What is the recommended starting dose of premixed insulin 70/30 (human insulin) at 0.3–0.4 units/kg/day, can the dose be divided two‑thirds in the morning and one‑third in the evening, and which 70/30 brand (Humulin 70/30 [insulin human] or Novolin 70/30 [insulin human]) is considered the best option in the Philippines?
What are the indications for CT angiography?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.